Abstract
Application of molecular biology techniques to the production of new vaccines against different strains of the Newcastle disease virus (NDV) has been the subject of recent research reports. Development of improved techniques for genome sequencing has led to the recognition of protective mechanisms and the identification of possible candidate antigens. Such procedures could generate meaningful results regarding the virulence determinants of NDV. This study proposed an in silico approach by assembling potential and conserved epitopic regions of hemagglutinin–neuraminidase (HN) and fusion (F) glycoproteins of NDV to induce multiepitopic responses against the virus. Epitope predictions showed that the hypothetical synthetic construct could induce immature B and T cell epitopes that expect a high immune response because of their location in four distinct parts of the construct, namely the head, stalk and the heptad repeated regions known as the HRA and HRB domains. Most regions of the chimeric construct were found to have high antigenic propensity and surface accessibility, which further confirmed the strategy for selection of precise continuous and discontinuous epitopes of HN and F antigens. Thermodynamic folding of mRNA structures revealed correct folding of the RNA construct, indicating good stability of the mRNA to increase the efficiency of translation in the target host. The three-dimensional structure of the native HN-F chimeric protein was successfully generated and validated as a proper model which may define reliability, structural quality and conformation.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alexander DJ, Manvell RJ, Frost KM, Pollitt WJ, Welchman D, Perry K (1997) Newcastle disease outbreak in pheasants in Great Britain in May 1996. Vet Rec 140(1):20–22
Amani J, Mousavi SL, Rafati S, Salmanian AH (2009) In silico analysis of chimeric espA, eae and tir fragments of Escherichia coli O157:H7 for oral immunogenic applications. Theor Biol Med Model 6:28. doi:10.1186/1742-4682-1186-1128
Amet N, Lee HF, Shen WC (2009) Insertion of the designed helical linker led to increased expression of tf-based fusion proteins. Pharm Res 26(3):523–528. doi:10.1007/s11095-008-9767-0
Angenon G, Van Montagu M, Depicker A (1990) Analysis of the stop codon context in plant nuclear genes. FEBS Lett 271:144–146. doi:10.1016/0014-5793(90)80392-V
Arai R, Ueda H, Kitayama A, Kamiya N, Nagamune T (2001) Design of the linkers which effectively separate domains of a bifunctional fusion protein. Protein Eng 14(8):529–532. doi:10.1093/protein/14.8.529
Armstrong EP (2007) Economic benefits and costs associated with target vaccinations. J Manag Care Pharm 13:12–15
Bai Y, Shen WC (2006) Improving the oral efficacy of recombinant granulocyte colony-stimulating factor and transferrin fusion protein by spacer optimization. Pharm Res 23(9):2116–2121. doi:10.1007/s11095-006-9059-5
Balen B, Krsnik-Rasol M (2007) N-glycosylation of recombinant therapeutic glycoproteins in plant systems. Food Technol Biotechnol 45:1–10
Baloria U, Akhoon BA, Gupta SK, Sharma S, Verma V (2012) In silico proteomic characterization of human epidermal growth factor receptor 2 (HER-2) for the mapping of high affinity antigenic determinants against breast cancer. Amino Acids 42(4):1349–1360. doi:1310.1007/s00726-00010-00830-x
Bashford D (2004) Macroscopic electrostatic models for protonation states in proteins. Front Biosci 9:1082–1099. doi:10.2741/1187
Berzofsky JA, Ahlers JD, Belyakov IM (2001) Strategies for designing and optimizing new generation vaccines. Nat Rev Immunol 1(3):209–219. doi:10.1038/35105075
Bosch D, Schots A (2010) Plant glycans: friend or foe in vaccine development? Expert Rev Vaccines 9(8):835–842. doi:810.1586/erv 1510.1583
Chen X, Zaro JL, Shen WC (2012) Fusion protein linkers: property, design and functionality. Adv Drug Deliv Rev. doi:10.1016/j.addr.2012.09.039
De Groot AS, Berzofsky JA (2004) From genome to vaccine-new immunoinformatics tools for vaccine design. Methods 34(4):425–428. doi:10.1016/j.ymeth.2004.06.004
De Groot AS, McMurry J, Marcon L, Franco J, Rivera D, Kutzler M, Weiner D, Martin B (2005) Developing an epitope-driven tuberculosis (TB) vaccine. Vaccine 23(17–18):2121–2131. doi:10.1016/j.vaccine.2005.01.059
Dortmans JC, Koch G, Rottier PJ, Peeters BP (2011) Virulence of newcastle disease virus: what is known so far? Vet Res 42(1):122. doi:110.1186/1297-9716-1142-1122
Doytchinova IA, Flower DR (2007) VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines. BMC Bioinform 8:4. doi:10.1186/1471-2105-8-4
Dunker AK, Lawson JD, Brown CJ, Williams RM, Romero P, Oh JS, Oldfield CJ, Campen AM, Ratliff CM, Hipps KW, Ausio J, Nissen MS, Reeves R, Kang C, Kissinger CR, Bailey RW, Griswold MD, Chiu W, Garner EC, Obradovic Z (2001) Intrinsically disordered protein. J Mol Graph Model 19(1):26–59. doi:10.1016/S1093-3263(00)00138-8
Earp LJ, Delos SE, Park HE, White JM (2005) The many mechanisms of viral membrane fusion proteins. Curr Top Microbiol Immunol 285:25–66
Emini EA, Hughes JV, Perlow DS, Boger J (1985) Induction of hepatitis A virus-neutralizing antibody by a virus-specific synthetic peptide. J Virol 55(3):836–839
George RA, Heringa J (2002) An analysis of protein domain linkers: their classification and role in protein folding. Protein Eng 15(11):871–879. doi:10.1093/protein/15.11.871
Gomord V, Fitchette AC, Menu-Bouaouiche L, Saint-Jore-Dupas C, Plasson C, Michaud D, Faye L (2010) Plant-specific glycosylation patterns in the context of therapeutic protein production. Plant Biotechnol J 8(5):564–587. doi:510.1111/j.1467-7652.2009.00497.x
Gupta SK, Singh A, Srivastava M, Akhoon BA (2009) In silico DNA vaccine designing against human papillomavirus (HPV) causing cervical cancer. Vaccine 28(1):120–131. doi:110.1016/j.vaccine.2009 1009.1095
Gustafsson C, Govindarajan S, Minshull J (2004) Codon bias and heterologous protein expression. Trends Biotechnol 22(7):346–353. doi:10.1016/j.tibtech.2004.04.006
Henry I, Sharp PM (2007) Predicting gene expression level from codon usage bias. Mol Biol Evol 24(1):10–12. doi:10.1093/molbev/msl148
Hines NL, Miller CL (2012) Avian paramyxovirus serotype-1: a review of disease distribution, clinical symptoms, and laboratory diagnostics. Vet Med Int 2012:708216. doi:10.1155/2012/708216
Huang Z, Elankumaran S, Panda A, Samal SK (2003) Recombinant Newcastle disease virus as a vaccine vector. Poult Sci 82(6):899–906
Huang Z, Panda A, Elankumaran S, Govindarajan D, Rockemann DD, Samal SK (2004) The hemagglutinin–neuraminidase protein of Newcastle disease virus determines tropism and virulence. J Virol 78(8):4176–4184. doi:10.1128/JVI.78.8.4176- 4184.2004
Ikemura T (1981) Correlation between the abundance of Escherichia coli transfer RNAs and the occurrence of the respective codons in its protein genes: a proposal for a synonymous codon choice that is optimal for the E. coli translational system. J Mol Biol 151:389–409. doi:10.1016/0022-2836(81)90003-6
Iorio RM, Syddall RJ, Sheehan JP, Bratt MA, Glickman RL, Riel AM (1991) Neutralization map of the hemagglutinin–neuraminidase glycoprotein of Newcastle disease virus: domains recognized by monoclonal antibodies that prevent receptor recognition. J Virol 65(9):4999–5006
Irving MB, Pan O, Scott JK (2001) Random-peptide libraries and antigen-fragment libraries for epitope mapping and the development of vaccines and diagnostics. Curr Opin Chem Biol 5(3):314–324. doi:10.1016/S1367-5931(00)00208-8
Kolaskar AS, Tongaonkar PC (1990) A semi-empirical method for prediction of antigenic determinants on protein antigens. FEBS Lett 276(1–2):172–174. doi:10.1016/0014-5793(90)80535-Q
Kozak M (1984) Compilation and analysis of sequences upstream from the translational start site in eukaryotic mRNAs. Nucleic Acids Res 12(2):857–872
Kozak M (1989) The scanning model for translation: an update. J Cell Biol 108(2):229–241
Kukic P, Nielsen JE (2010) Electrostatics in proteins and protein-ligand complexes. Future Med Chem 2(4):647–666. doi:10.4155/fmc.10.6
Lakshmi PTV, Subhashini S (2010) In silico sequence specific analysis of ERBB2 RTK alterations responsible for neuroectodermal tumors of Homo sapiens. J Bioinform Seq Anal 2:75–84
Lamb RA, Jardetzky TS (2007) Structural basis of viral invasion: lessons from paramyxovirus F. Curr Opin Struct Biol 17(4):427–436. doi:10.1016/j.sbi.2007.08.016
Lamb RA, Kolakofsky D (2001) Paramyxoviridae: the viruses and their replication. In: Knipe DM, Howley PM (eds) Fields virology, 4th edn. Lippincott Williams and Wilkins, Philadelphia, pp 1305–1340
Lovell SC, Davis IW, Arendall WB, De Bakker PI, Word JM, Prisant MG, Richardson JS, Richardson DC (2003) Structure validation by C-alpha geometry: phi, psi and C-beta deviation. Proteins 50(3):437–450. doi:10.1002/prot.10286
McGinnes LW, Morrison TG (1995) The role of individual oligosaccharide chains in activities of the HN glycoprotein of Newcastle disease virus. Virology 212:398–410. doi:10.1006/viro 1995.1497
McGinnes LW, Sergel T, Reitter J, Morrison T (2001) Carbohydrate modifications of the NDV fusion protein heptad repeat domains influence maturation and fusion activity. Virology 283:332–342. doi:10.1006/viro 2001.0899
Meeusen EN, Walker J, Peters A, Pastoret PP, Jungersen G (2007) Current status of veterinary vaccines. Clin Microbiol Rev 20(3):489–510. doi:10.1128/CMR.00005-07
Mia Kim L, Suarez DL, Afonso CL (2008) Detection of a broad range of class I and II Newcastle disease viruses using a multiplex real-time reverse transcription polymerase chain reaction assay. J Vet Diagn Invest 20(4):414–425. doi:10.1177/104063870802000402
Miller PJ, Decanini EL, Afonso CL (2010) Newcastle disease: evolution of genotypes and the related diagnostic challenges. Infect Genet Evol 10(1):26–35. doi:10.1016/j.meegid.2009.09.012
Nazarian S, Mousavi Gargari SL, Rasooli I, Amani J, Bagheri S, Alerasool M (2012) An in silico chimeric multi subunit vaccine targeting virulence factors of enterotoxigenic Escherichia coli (ETEC) with its bacterial inbuilt adjuvant. J Microbiol Met 90:36–45. doi:10.1016/j.mimet.2012.04.001
Ordu E, Karagüler NG (2012) Protein engineering applications on industrially important enzymes: Candida methylica FDH as a case study. In: Kauyama P (ed) Protein Engineering. In Tech, pp 75–98
Parker JM, Guo D, Hodges RS (1986) New hydrophilicity scale derived from high-performance liquid chromatography peptide retention data: correlation of predicted surface residues with antigenicity and X-ray-derived accessible sites. Biochemistry 25(19):5425–5432
Rosenberg IIM (2005) Protein analysis and purification: Bench top techniques. Birkhauser, Boston
Rout S (2007) The role of Newcastle disease virus internal proteins in pathogenesis. Dissertation, University of Maryland
Russell CJ, Jardetzky TS, Lamb RA (2004) Conserved glycine residues in the fusion peptide of the paramyxovirus fusion protein regulate activation of the native state. J Virol 78(24):13727–13742. doi:10.1128/JVI.78.24.13727-1 3742.2004
Ryan EJ, Daly LM, Mills KH (2001) Immunomodulators and delivery systems for vaccination by mucosal routes. Trends Biotechnol 19(8):293–304. doi:10.1016/S0167-7799(01)01670-5
Sharp PM, Li WH (1987) The codon adaptation index–a measure of directional synonymous codon usage bias, and its potential applications. Nucleic Acids Res 15(3):1281–1295
Sinkovics JG, Horvath JC (2000) Newcastle disease virus (NDV): brief history of its oncolytic strains. J Clin Virol 16(1):1–15. doi:10.1016/S1386-6532(99)00072-4
Soria-Guerra RE, Moreno-Fierros L, Rosales-Mendoza S (2011) Two decades of plant-based candidate vaccines: a review of the chimeric protein approaches. Plant Cell Rep 30(8):1367–1382. doi:1310.1007/s00299-00011-01065-00293
Sun J, Chen M, Xu J, Luo J (2005) Relationships among stop codon usage bias, its context, isochores, and gene expression level in various eukaryotes. J Mol Evol 61(4):437–444. doi:10.1007/s00239-004-0277-3
Susta L, Miller PJ, Afonso CL, Estevez C, Yu Q, Zhang J, Brown CC (2010) Pathogenicity evaluation of different Newcastle disease virus chimeras in 4-week-old chickens. Trop Anim Health Prod 42(8):1785–1795. doi:1710.1007/s11250-11010-19638-11257
Wan H, Wootton JC (2000) A global compositional complexity measure for biological sequences: AT-rich and GC-rich genomes encode less complex proteins. Comput Chem 24(1):71–94. doi:10.1016/S0097-8485(00)80008-X
Wang Y, Wu W, Negre NN, White KP, Li C, Shah PK (2011) Determinants of antigenicity and specificity in immune response for protein sequences. BMC Bioinform 12(251):1–13. doi:10.1186/1471-2105-1112-1251
Wilkinson DL, Harrison RG (1991) Predicting the solubility of recombinant proteins in Escherichia coli. Biotechnology 9(5):443–448. doi:10.1038/nbt0591-443
Wu YJ, Fan CY, Li YK (2009) Protein purification involving a unique auto-cleavage feature of a repeated EAAAK peptide. J Chromatogr B 877(31):4015–4021. doi:4010.1016/j.jchromb.2009 4010.4009
Xiao S, Huang Y, Xiao Y (2003) Local complexity of protein sequences. Int J Mod Phys C 14:1191–1199
Yang ZQ, Liu QQ, Pan ZM, Yu HX, Jiao XA (2007) Expression of the fusion glycoprotein of Newcastle disease virus in transgenic rice and its immunogenicity in mice. Vaccine 25(4):591–598. doi:10.1016/j.vaccine.2006.08.016
Yin HS, Wen X, Paterson RG, Lamb RA, Jardetzky TS (2006) Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation. Nature 439:38–44. doi:10.1038/nature04322
Yuan P, Swanson KA, Leser GP, Paterson RG, Lamb RA, Jardetzky TS (2011) Structure of the Newcastle disease virus hemagglutinin–neuraminidase (HN) ectodomain reveals a four-helix bundle stalk. Proc Natl Acad Sci USA 108(36):14920–14925. doi:14910.11073/pnas.1111691108
Yusoff K, Nesbit M, McCartney H, Meulemans G, Alexander DJ, Collins MS, Emmerson PT, Samson ACR (1989) Location of neutralizing epitopes on the fusion protein of Newcastle disease virus strain Beaudette C. J Gen Virol 70:3105–3109. doi:10.1099/0022-1317-70-11-3105
Zhang Y (2008) I-TASSER server for protein 3D structure prediction. BMC Bioinform 9:40. doi:10.1186/1471-2105-1189-1140
Acknowledgments
This work was financially supported by the National Institute of Genetic Engineering and Biotechnology (NIGEB grant number: 447).
Conflict of interest
Mohammad Javad Motamedi, Jafar Amani, Shahla Shahsavandi and Ali Hatef Salmanian declare that they have no conflicts of interest.
Human and Animal Rights
This article does not contain any studies with human or animal subjects.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Motamedi, M.J., Amani, J., Shahsavandi, S. et al. In Silico Design of Multimeric HN-F Antigen as a Highly Immunogenic Peptide Vaccine Against Newcastle Disease Virus. Int J Pept Res Ther 20, 179–194 (2014). https://doi.org/10.1007/s10989-013-9380-x
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10989-013-9380-x